Long-read sequencing market seen reaching $3.74B by 2030

The Business Research Company says the long-read sequencing market will grow from $1.15 billion in 2025 to $1.46 billion in 2026, then reach $3.74 billion by 2030. The report points to rising genetic disease diagnoses, wider clinical adoption, lower sequencing costs and AI-driven analysis as the main growth catalysts.

Why it matters: - Long-read sequencing is moving from a research tool toward broader clinical use. - The technology can improve detection of structural variants, complex mutations and hard-to-read genomic regions. - Faster adoption could improve diagnosis for rare and genetic diseases and support more personalized care.

What happened: - The Business Research Company released its Long-Read Sequencing Market Report 2026, covering market size, trends and global forecasts through 2035. - The report values the market at $1.15 billion in 2025 and projects $1.46 billion in 2026. - The report forecasts the market will reach $3.74 billion by 2030. - The report was published Aug. 14, 2026, in London. - Download a free sample of the report. - View the full report.

The details: - The report cites a 26.8% compound annual growth rate for the jump from 2025 to 2026. - It projects a 26.5% CAGR through 2030. - Growth drivers include the limits of short-read sequencing, stronger genomics research, nanopore sequencing advances, demand for better genome assemblies and higher life sciences investment. - Future growth factors include wider clinical adoption, lower sequencing costs, AI integration for data analysis, growth in oncology diagnostics and population-scale genomics programs. - Emerging trends include more uptake of long-read sequencing, better structural variant detection, hybrid sequencing workflows, more use in rare disease genomics and more complex genome assembly applications. - Long-read sequencing reads DNA or RNA in long continuous stretches, often thousands to millions of base pairs. - The approach supports more accurate genome assembly and better analysis of complex genomic regions. - Genetic disease prevalence is a major growth engine for the market. - Genetic disorders can be inherited or spontaneous and can affect health and development in different ways. - The report says improved diagnostic technology is helping detect these conditions earlier and more precisely. - Long-read sequencing helps identify structural variants and complicated mutations more reliably than traditional methods. - The technology can reduce diagnostic uncertainty and support treatment planning and clinical decisions. - The UK’s Cystic Fibrosis Trust reported the number of people living with cystic fibrosis rose from 11,148 in 2022 to 11,318 in 2023. - The report says that rise illustrates demand for more advanced genetic diagnostic tools. - North America held the largest share of the global long-read sequencing market in 2025. - Asia-Pacific is projected to grow fastest during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated technology and trend analysis.

Between the lines: - The market outlook reflects a shift from basic sequencing volume to higher-value interpretation and clinical utility. - AI and hybrid sequencing suggest buyers want better accuracy and easier analysis, not just more raw data. - Regional growth in Asia-Pacific points to broader genomics investment outside established North American markets.

What's next: - The report expects clinical uptake and oncology use cases to keep expanding as costs fall. - Population genomics programs and rare disease applications could add new demand over the forecast period. - The Business Research Company is positioning its 2026 report series around more forecasting tools and market scoring features.

The bottom line: - Long-read sequencing is forecast to stay one of genomics’ fastest-growing segments as clinical demand, AI tools and rare disease diagnostics move it deeper into mainstream use.